Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration

Luke C. Swenson,^a Bryan Cobb,^b Anna Maria Geretti,^c P. Richard Harrigan,^a Mario Poljak,^d Carole Seguin-Devaux,^e Chris Verhofstede,^f Marc Wirten,^g Alessandra Amendola,^h Jurg Boni,ⁱ Thomas Bourlet,^j Jon B. Huder,ⁱ Jean-Claude Karasi,^k Snjezana Zidovec Lepej,^l Maja M. Lunar,^d Odette Mukabayire,^k Rob Schuurman,^m Janez Tomažič,^d Kristel Van Laethem,ⁿ Linos Vandekerckhove,^f Annemarie M. J. Wensing,^m on behalf of the International Viral Load Assay Collaboration

BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada^a; Roche Molecular Systems, Pleasanton, California, USA^b; Institute of Infection and Global Health, University of Liverpool, United Kingdom^c; University of Ljubljana, Institute of Microbiology and Immunology, Ljubljana, Slovenia^d; Laboratory of Retrovirology, CRP-Santé, Luxembourg, Luxembourg^e; AIDS Reference Laboratory, Ghent University, Ghent, Belgium^f; AP-HP, Pitié-Salpêtrière Hospital, INSERM U 943, and Pierre et Marie Curie University Paris, Paris, France^g; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy^h; Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerlandⁱ; Laboratory of Virology, CHU de Saint-Etienne, Saint-Etienne, France^j; Ministry of Health, National Reference Laboratory, Kigali, Rwanda^k; University Hospital for Infectious Diseases, Zagreb, Croatia^l; University Medical Center Utrecht, Utrecht, Netherlands^m; Clinical and Epidemiological Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgiumⁿ

Low-level viremia during antiretroviral therapy and its accurate measurement are increasingly relevant. Here, we present an international collaboration of 4,221 paired blood plasma viral load (pVL) results from four commercial assays, emphasizing the data with low pVL. The assays compared were the Abbott RealTime assay, the Roche Amplicor assay, and the Roche TaqMan version 1 and version 2 assays. The correlation between the assays was 0.90 to 0.97. However, at a low pVL, the correlation fell to 0.45 to 0.85. The observed interassay concordance was higher when detectability was defined as 200 copies/ml than when it was defined as 50 copies/ml. A pVL of ~100 to 125 copies/ml by the TaqMan version 1 and version 2 assays corresponded best to a 50-copies/ml threshold with the Amplicor assay. Correlation and concordance between the viral load assays were lower at a low pVL. Clear guidelines are needed on the clinical significance of low-level viremia.

The level of HIV-1 RNA in blood plasma (viral load) is arguably the most important surrogate marker in the treatment of HIV infection (1). For over a decade, the endpoint PCR-based Roche Cobas Amplicor HIV-1 Monitor test (versions 1 and 1.5) (Amplicor) (2) was a widely used viral load assay and was in use in both clinical trials and routine practice. Many clinical trials have used a viral load considered to be “undetectable” by the Amplicor assay (i.e., one that is <50 HIV-1 RNA copies/ml) as the endpoint for measuring the efficacy of antiretroviral therapy. Various guidelines have adopted the same threshold as the goal of therapy for all patients, regardless of previous treatment experience (1, 3–5). After many years of using the Amplicor test, the real-time PCR-based Roche Cobas AmpliPrep/Cobas TaqMan real-time quantitative human immunodeficiency virus type 1 (HIV-1) test (TaqMan) began to replace the Amplicor test in early 2008. There are two versions of the TaqMan assay; version 2 has replaced version 1 across Europe, Asia, and North America. The TaqMan versions 1 and 2 assays have lower limits of quantitation of 40 and 20 copies/ml, respectively (6). Other assays based on real-time PCR technology have also been implemented in clinical settings, including the Abbott RealTime HIV-1 assay (RealTime) (Abbott Molecular, Inc.) and the Qiagen artus HIV-1 QS-RGQ assay (7, 8), which have lower limits of quantitation of 40 and 45 copies/ml, respectively (9).

Although generally these assays tend to give roughly comparable results (10), their manufacturers have reported that variation and error tend to increase at the lower limits of quantitation of the assays. Furthermore, there have been reports that real-time PCR-based assays tend to identify more patients as having low-level viremia than does the Amplicor test (10–15). Multiple studies have documented variation between these assays when measuring samples with low viral load levels (6, 13, 15–21).

Therapy outcomes have been shown to be influenced by low-

level viremia in some studies (16, 22–28) but not others (29–32), in part reflecting differences in the measured outcomes. However, the overall clinical relevance of low-level viremia remains controversial. Accordingly, some clinical guidelines (4, 33) have set higher thresholds (~200 copies/ml) for defining virologic failure, while others (1) are more conservative and recommend that patients with lower levels of viremia be reviewed due to a potential risk of virological rebound.

A significant clinical question has been to determine the relevance of low-level viremia. In order to properly address this question, an assessment of the fundamental agreement of the various assays for defining low-level viremia must be undertaken. Given that the viral load assays mentioned above differ in their reported lower limits of quantitation and detection (LLQ and LLD, respectively) (34), and given the lack of definitive guidelines on the management of low-level viremia, our aim was to assess the basic comparability of various viral load assays at these lower viral loads. Thus, we established a large international collaborative group to assemble comparisons of the Amplicor 1.5, RealTime, TaqMan version 1, and TaqMan version 2 viral load assays at low viral loads.

Received 5 September 2013 Returned for modification 22 October 2013

Accepted 26 November 2013

Published ahead of print 4 December 2013

Editor: Y.-W. Tang

Address correspondence to Annemarie M. J. Wensing, a.m.j.wensing@umcutrecht.nl.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JCM.02461-13

FIG 1 Comparisons among viral load assays. (A and B) Shown is the correlation of the TaqMan assays with either the Amplicor assay (A) or the RealTime assay (B). Comparisons involving TaqMan version 1 are shown with filled gray circles, while those involving TaqMan version 2 are shown with open squares. The R^2 values for all correlations are shown in the legends. (C to F) The bottom four panels show Bland-Altman difference plots comparing different viral load assays. Shown are comparisons of the Amplicor assay with the TaqMan version 1 (C) or version 2 (D) assay and of the RealTime assay with the TaqMan version 1 (E) or version 2 (F) assay. The bias (mean difference between the assays) is shown as a solid horizontal line, and the 95% limits of agreement are shown with dashed lines at ± 1.96 standard deviations.

MATERIALS AND METHODS

A total of 14 sites from Europe, North America, and Africa contributed 4,221 paired viral load results obtained by different assays performed using the same sample. The numbers of data points in the comparisons were

1,384 (Amplicor versus TaqMan version 1), 365 (Amplicor versus TaqMan version 2), 827 (RealTime versus TaqMan version 1), 1,230 (RealTime versus TaqMan version 2), and 415 (TaqMan version 1 versus TaqMan version 2). The subtype data, when provided, were collected independently at each

TABLE 1 Correlation coefficients for interassay comparisons at viral loads of <1,000 copies/ml^a

Assay detection (at <1,000 copies/ml)	Correlation coefficients of discordant results of ≥1,000 copies/ml			
	Amplicor	RealTime	TaqMan v1	TaqMan v2
Amplicor		NA ^b	0.52	0.85
RealTime	NA		0.74	0.82
TaqMan v1	0.45	0.54		0.69
TaqMan v2	0.80	0.78	0.68	

^a Correlation coefficients of the interassay comparisons were calculated using the results with a restriction of at least one viral load assay giving a result of <1,000 copies/ml. The assay restricted to <1,000 copies/ml is shown in the left-hand column, and its comparator assay is indicated in the columns. For example, when TaqMan v1 was restricted to values of <1,000 copies/ml, the matching Amplicor test results had an *R* value of 0.45. Conversely, when the Amplicor test was restricted to <1,000 copies/ml, the matching TaqMan v1 results had an *R* value of 0.52.

^b NA, not available.

site by various in-house methods. Ethical approval at the individual collaborating centers was based on local regulations. There were insufficient numbers of paired results from both the Amplicor and RealTime tests, so comparisons between them were excluded. Correlation and Bland-Altman analyses were performed using paired data points. If a viral load value fell below the LLQ of a given assay or was classified as not detected, the value was imputed as 1 copy less than the LLQ (e.g., 49 for an LLQ of 50 copies/ml).

RESULTS

The correlations between the viral load assays performed on the same sets of samples are shown in Fig. 1A and B. Compared to the Amplicor assay, the TaqMan version 1 assay had a correlation coefficient (Pearson's *R* value) of 0.90, and the TaqMan version 2 assay had an *R* value of 0.97. The correlation coefficients of the TaqMan version 1 and version 2 assays were also 0.90 and 0.97 compared to the RealTime assay. Although there were a small number of data points comparing the Amplicor and RealTime tests (*n* = 56), these assays had a correlation coefficient of 0.88 (data not shown).

We then restricted our analyses to samples where at least one assay gave a viral load result of <1,000 copies/ml, which is a common definition of low-level viremia. The lower correlation coefficients were obtained when the analyses were performed on low-level viremia samples (Table 1). For example, at <1,000 copies, the RealTime and TaqMan version 2 assays had *R* values of approximately 0.8 compared with an *R* value of 0.97 for the comparison over the full range of viral load values. All correlations between the assays were lower when the data were restricted to viral loads of <1,000 copies/ml (Table 1).

TABLE 2 Discordance for HIV-1 RNA levels at <50 copies/ml

Assay (at <50 copies/ml)	% discordant results of ≥50 copies/ml (no. of discordant samples/total no. of samples) ^a			
	Amplicor	RealTime	TaqMan v1	TaqMan v2
Amplicor		NA	73 (598/819)	6 (10/172)
RealTime	NA		27 (63/230)	13 (73/569)
TaqMan v1	11 (27/248)	23 (49/216)		24 (50/206)
TaqMan v2	5 (8/170)	7 (40/356)	25 (51/207)	

^a Shown are the percentages of results that were discordant between the assays at a threshold of 50 copies/ml. NA, not available.

TABLE 3 Discordance for HIV-1 RNA levels at <200 copies/ml^a

Assay (at <200 copies/ml)	% discordant results of ≥200 copies/ml (no. of discordant samples/total no. of samples)			
	Amplicor	RealTime	TaqMan v1	TaqMan v2
Amplicor		NA	5 (58/1,161)	3 (7/204)
RealTime	NA		10 (37/356)	7 (49/728)
TaqMan v1	7 (85/1,188)	16 (59/378)		7 (25/236)
TaqMan v2	3 (7/204)	3 (22/701)	1 (3/314)	

^a Shown are the percentages of results that were discordant between the assays at a threshold of 200 copies/ml. The percentage of discordant samples decreased for all comparisons when a threshold of 200 copies/ml was used, compared to a 50-copies/ml threshold. NA, not available.

Since correlation coefficients do not account for the fact that one assay may provide consistently higher or lower values relative to the other assay, pairwise Bland-Altman plots were used to further assess the level of agreement (Fig. 1C to F). The 95% level of agreement ranged from −0.61 to 0.75 log when the TaqMan version 1 assay was compared with the Amplicor assay (with 55/1,384 [4%] samples outside this range) and ranged from −1.2 to 1.0 log when the RealTime test was compared with the Amplicor test (with 33/827 [4%] samples outside this range). Samples outside the 95% level of agreement were mostly due to relative underreporting for the TaqMan version 1 test (40 samples and 33 samples for the two comparisons described above, respectively). For the TaqMan version 2 test, the 95% level of agreement versus the Amplicor test was −0.89 to 0.85 (with 1/365 [0.3%] samples below and 14/365 [4%] samples above this range) and versus the RealTime assay was −0.80 to 0.60 (with 19/1,230 [1.5%] samples below and 43/1,230 [3.5%] samples above this range). Comparing the TaqMan version 1 and version 2 assays, approximately 4% (16/415) of the results fell outside the 95% level of agreement, all due to relative underreporting for the TaqMan version 1 test (data not shown).

As previously reported (35), HIV subtype may have partially contributed to assay discordance. The HIV subtype was available for 1,493 of the 4,221 samples (35%). Analyses involving the Amplicor assay were excluded due to a low proportion having HIV subtype information (10% [175/1,749]). Of 25 samples for which the TaqMan version 1 test gave results of at least 1.5 log copies below those of the RealTime test, the most common subtypes were CRF02 (8 samples), subtype F (5 samples), subtype B (4 samples), CRF01 (3 samples), CRF09 (2 samples), CRF14 (2 samples), and subtype G (1 sample). Of 3 samples for which the TaqMan version 2 results were >1.5 log copies below those of the RealTime test, the subtypes were C, CRF01, and CRF02. There were 7 samples that TaqMan version 1 underquantified by >1.5 log compared to TaqMan version 2; 6 of these were CRF02 and 1 was subtype G.

Next, we analyzed assay discordance at a threshold of either 50 or 200 copies/ml (Tables 2 and 3). There was higher concordance between the assays when detectability was defined as ≥200 copies/ml than when defined as ≥50 copies/ml. Overall, 27% (63/230) and 13% (73/569) of the samples with RealTime assay results of <50 copies/ml were above the 50-copies/ml threshold using the TaqMan version 1 and TaqMan version 2 assays, respectively, with median (range) HIV-1 RNA levels of 84 (50 to 394) copies/ml and 99 (51 to 1,620) copies/ml, respectively. For samples with Amplicor assay viral loads of <50 copies/ml, 73% (598/819) of the samples were >50 copies/ml by the TaqMan version 1 assay and 6%

FIG 2 Proportion of samples with <50 copies/ml by the Amplicor assay as a function of the TaqMan version 1 or version 2 assay. The proportion of samples with Amplicor results of <50 copies/ml decreased at higher TaqMan version 1 and version 2 strata. (A) Proportion of samples with undetectable viral loads by the Amplicor assay (<50 copies/ml) as a function of the viral load reported by the TaqMan version 1 assay. (B) Similar plot as in panel A but as a function of the viral load reported by the TaqMan version 2 assay. For both TaqMan assays, when either had a viral load result of up to 100 copies/ml, a majority of the corresponding samples were actually undetectable by the Amplicor assay.

(10/172) of the samples were >50 copies/ml by the TaqMan version 2 assay, with median (range) HIV-1 RNA levels of 76 (50 to 247) copies/ml and 85 (70 to 164) copies/ml, respectively. Inter-assay discordance decreased substantially when a 200-copies/ml threshold was used (Table 3). For example, the discordance between the Amplicor and TaqMan version 1 assays dropped from 73% at a 50-copies/ml threshold to 5% at a 200-copies/ml threshold.

Consistent with the findings of higher concordance at higher thresholds, the percentage of results with <50 copies/ml by the Amplicor test decreased in a stepwise pattern as the reported viral load using the TaqMan version 1 test increased (Fig. 2A). The point at which the proportion of Amplicor test results with >50 copies/ml reached a majority of samples occurred in the range of 100 to 124 copies/ml according to the TaqMan version 1 test. In other words, most samples (71%) with TaqMan version 1 test results up to 125 copies/ml were actually <50 copies/ml according to the Amplicor test, with a median of 49 copies/ml (interquartile range [IQR], 49 to 59). For the TaqMan version 2 test, this threshold was approximately 100 copies/ml (Fig. 2B).

DISCUSSION

We present here a large comparison of >4,000 paired viral load assay results. We also assessed interassay discordance at low viral load thresholds and found a lower interassay correlation at viral loads of <1,000 copies/ml, compared to the full dynamic ranges of the assays. This range is of clinical importance since many patients are on suppressive or near-suppressive antiretroviral therapies. Indeed, in this study, we deliberately sought a high number of low viral load data points in order to assess the concordance between the assays when performed near their lower limits of quantitation.

We found that correlation between the assays was lower at low viral loads. Discordance decreased when a threshold of 200 copies/ml was used rather than when a 50-copy threshold was used. As was previously reported (19, 36), we confirm that the TaqMan version 2 assay does not appear to have the severe underquantification reported with the TaqMan version 1 assay. However, both TaqMan assays have higher rates of detectability than the Amplicor and RealTime assays. There are a number of factors that may contribute to assay discordance, including viral blips, sample handling, contamination, or differences in the assay primers used (14, 31, 37–42). Furthermore, the assays themselves have inherently lower precision, reproducibility, and sensitivity at the lower ends of their dynamic ranges, which likely contributes to interassay disagreement at low viral loads. Assays exist to quantify viral loads even to single-copy levels, and commercial assays can be modified to accommodate low viral loads (43–46). However, these often require large volumes of blood plasma, up to 30 ml in some cases (43), and this precludes their routine use in the clinic setting.

Our data also indicate that a viral load of approximately 100 to 125 copies/ml according to the TaqMan version 1 or TaqMan version 2 assays may correspond to a threshold of detectability of >50 copies/ml by the Amplicor assay, an HIV viral load assay that was widely used for >10 years. Further, we found that interassay concordance for all viral load assays is much higher at a 200-copies/ml threshold than at a 50-copies/ml threshold. Some HIV clinical guidelines (4, 33) have defined higher cutoffs of 200 to 250 copies/ml for low-level viremia, partially in response to the higher rates of detectability seen with this next generation of assays. Thus, the prevalence and extent of low-level viremia may depend a great

deal on the specific viral load assay in use, and the clinical relevance of the detectable viral load may likewise vary with the assay and threshold defining what is detectable.

The strengths of this data set are its size and the focus on low viral loads that are close to the limits of detection of the assays, but there are also some limitations which should be acknowledged. While the focus of this study was on low viral load levels, there is also variation at the high viral load strata (47). As this was an international collaboration, various methods were used to generate the assay results, and biases inherent in the collections of convenience sample sets in some centers may have had unknown effects. Selection bias may have also influenced the results; for instance, the Vancouver site deliberately retested samples with the Amplicor assay that had TaqMan version 1 assay viral loads of <250 copies/ml (29). The handling procedures varied at different sites as well, and this has been known to impact the results (48), even though all the laboratories reported using EDTA tubes for sample collection and storage. The lack of clinical follow-up for patients experiencing low-level viremia makes the interpretation of these results difficult to situate in a clinical context. Finally, older assays were examined in this study. The TaqMan version 1 assay is being phased out or is no longer in use, and the Amplicor assay has been discontinued. However, although comparisons to the Amplicor assay are of limited relevance to current practice, they are essential to contextualizing newer assays, since the Amplicor assay has dominated the field for so long.

Additional data are needed to determine the impact of low-level viremia on outcomes, such as higher viral rebound, CD4 count, therapy changes, and drug resistance, as well as what the cost impacts are for recalling patients for retesting and changing treatment (41). The high variability around the threshold of detectability of the viral load assays should be noted, since many patients have viral loads in this range. This variability makes defining low-level viremia itself difficult to achieve. We found that agreement between these assays was improved using a 200-copies/ml threshold. Indeed, this threshold is consistent with the current HIV treatment guidelines from the Department of Health and Human Services (DHHS) (4). However, this study does not include clinical follow-up, making firm clinical guidelines difficult to establish based on these data. We suggest that similar large-scale collaborations focusing on low-level viremia that are paired with clinical follow-up would be extremely valuable in establishing such clinical guidelines.

ACKNOWLEDGMENTS

We thank Antoinet van Kessel and the European Society for Antiviral Resistance for their assistance in collecting the data set.

Bryan Cobb is an employee of Roche, which manufactures some of the viral load assays used in this study. Roche contributed data comparing the Amplicor and TaqMan version 2 assays.

L.C.S., B.C., A.M.G., P.R.H., M.P., C.S.-D., C.V., M.W., and A.M.J.W. formed the writing committee for this article, and they contributed data and contributed to the analysis and writing of the paper. A.A., J.B., T.B., J.B.H., J.-C.K., S.Z.L., M.M.L., O.M., R.S., J.T., K.V.L., and L.V. formed the scientific committee for this article, and they contributed data and formative input.

REFERENCES

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treat-

- ment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA* 308:387–402. <http://dx.doi.org/10.1001/jama.2012.7961>.
2. Sun R, Ku J, Jayakar H, Kuo JC, Brambilla D, Herman S, Rosenstrauss M, Spadaro J. 1998. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* 36:2964–2969.
 3. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gillece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. 2012. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. *HIV Med.* 13:1–85. <http://dx.doi.org/10.1111/j.1468-1293.2012.01029.x>.
 4. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2032. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, Washington, DC. <http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>.
 5. EACS. 2012. Guidelines version 6.1. European AIDS Clinical Society, Paris, France. http://www.sm.ee/fileadmin/meedia/Dokumendid/Tervisevaldkond/Tervishoid/EACSGuidelines_v6.1_Nov2012.pdf.
 6. Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A. 2013. Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. *Med. Microbiol. Immunol.* 202:67–75. <http://dx.doi.org/10.1007/s00430-012-0249-y>.
 7. Schutten M, Peters D, Back NK, Beld M, Beuselinck K, Foulongne V, Geretti AM, Pandiani L, Tiemann C, Niesters HG. 2007. Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. *J. Clin. Microbiol.* 45:1712–1717. <http://dx.doi.org/10.1128/JCM.02385-06>.
 8. Wall GR, Perinpanathan D, Clark DA. 2012. Comparison of the QIAGEN artus HIV-1 QS-RGQ test with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0. *J. Clin. Virol.* 55:62–66. <http://dx.doi.org/10.1016/j.jcv.2012.05.014>.
 9. Garcia-Diaz A, Labbett W, Clewley GS, Guerrero-Ramos A, Geretti AM. 2013. Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. *J. Clin. Virol.* 57:66–69. <http://dx.doi.org/10.1016/j.jcv.2013.01.006>.
 10. Oliver AR, Pereira SF, Clark DA. 2007. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR version 1.5 conventional PCR assay. *J. Clin. Microbiol.* 45:3616–3619. <http://dx.doi.org/10.1128/JCM.00221-07>.
 11. Lima V, Harrigan R, Montaner JSG. 2009. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. *J. Acquir. Immune Defic. Syndr.* 51:3–6. <http://dx.doi.org/10.1097/QAI.0b013e31819e721b>.
 12. Szabo S, Moffett LE, Cantwell-McNelis K, James CW, Joseph A. 2010. Low-level viremia associated with the use of TaqMan assay. *J. Int. Assoc. Physicians AIDS Care (Chic.)* 9:203–205. <http://dx.doi.org/10.1177/1545109710371131>.
 13. Geretti AM, Tong W, Fox Z, Labbett W, O'Shea S, Chrystie I, Smit E. 2009. The Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2.0 assay for HIV-1 RNA load measurement in plasma shows improved detection of non-B subtypes and increased levels of detection and reporting. *Abstr. PE20.6/1. HIV Med.* 10(Suppl 2):220. <http://dx.doi.org/10.1111/j.1468-1293.2009.00792.x>.
 14. Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, Honda M, Teruya K, Kikuchi Y, Oka S. 2009. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. *Clin. Infect. Dis.* 48:259–260. <http://dx.doi.org/10.1086/595706>.
 15. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, Cunningham PH. 2010. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. *J. Clin. Virol.* 49:249–253. <http://dx.doi.org/10.1016/j.jcv.2010.08.016>.
 16. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piarard D, Goubau P. 2012. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. *BMC Infect. Dis.* 12:100. <http://dx.doi.org/10.1186/1471-2334-12-100>.
 17. Amendola A, Milia MG, Ghisetti V, Brega C, Zaccaro P, Capobianchi MR. 2009. Accuracy of a commercial real-time polymerase chain reaction-based system for measurement of HIV RNA levels around the limit of quantification of the assay. *Clin. Infect. Dis.* 48:1630–1631; author reply 1631–1632. <http://dx.doi.org/10.1086/598990>.
 18. Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D. 2007. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche Cobas AMPLICOR HIV-1 MONITOR version 1.5 and the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. *J. Clin. Microbiol.* 45:3436–3438. <http://dx.doi.org/10.1128/JCM.00973-07>.
 19. Karasi JC, Dziezok F, Quenerry L, Försster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC. 2011. High correlation between the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1, version 2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. *J. Clin. Virol.* 52:181–186. <http://dx.doi.org/10.1016/j.jcv.2011.07.002>.
 20. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, Trabaud M-A, Tardy J-C, Morand P, Pozzetto B, Ecohard R, André P. 2011. HIV-1 load comparison using four commercial real-time assays. *J. Clin. Microbiol.* 49:292–297. <http://dx.doi.org/10.1128/JCM.01688-10>.
 21. Jennings C, Harty B, Granger S, Wager C, Crump JA, Fiscus SA, Bremer JW. 2012. Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. *J. Clin. Microbiol.* 50:2737–2747. <http://dx.doi.org/10.1128/JCM.00578-12>.
 22. Verhofstede C, Van Wanzeele F, Van Der Gucht B, Pelgrom J, Vandekerckhove L, Plum J, Vogelaers D. 2007. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml. *J. Med. Virol.* 79:1254–1260. <http://dx.doi.org/10.1002/jmv.20950>.
 23. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. *Clin. Infect. Dis.* 54:724–732. <http://dx.doi.org/10.1093/cid/cir936>.
 24. Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina J-M, de Truchis P. 2012. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. *PLoS One* 7:e36673. <http://dx.doi.org/10.1371/journal.pone.0036673>.
 25. Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA. 2001. Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. *J. Acquir. Immune Defic. Syndr.* 28:105–113. <http://dx.doi.org/10.1097/00126334-200110010-00001>.
 26. Henrich TJ, Wood BR, Kuritzkes DR. 2012. Increased risk of virologic rebound in patients on antiviral therapy with isolated detectable viral loads <48 copies/mL by Taqman RT-PCR assay. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Sitges, Spain.
 27. Alvarez M, Chueca N, Guillot V, Pena A, Munoz LP, Hernandez-Quero J, Garcia F. 2012. Plasma HIV-1 viral load below 50 using the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test (Roche) is also associated to a higher risk of virologic rebound. *Abstr. O_23. European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, Barcelona, Spain.*
 28. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. *J. Acquir. Immune Defic. Syndr.* 60:473–482. <http://dx.doi.org/10.1097/QAI.0b013e3182567a57>.
 29. Harrigan R, Sherlock C, Hogg RS, Wynhoven B, Chui C, Swenson L, Lima VD, Montaner J. 2011. What should be the primary virological endpoint in clinical trials of ARV efficacy? *Abstr. 661. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA.*
 30. Manavi K. 2008. The significance of low-level plasma HIV viral load on Cobas TaqMan HIV-1 assays for patients with undetectable plasma viral load on Cobas Amplicor monitor version 1.5. *HIV Clin. Trials* 9:283–286. <http://dx.doi.org/10.1310/hct0904-283>.
 31. Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, Lima VD, Montaner JSG, Harrigan PR. 2012. Technical and regulatory shortcom-

- ings of the TaqMan version 1 HIV viral load assay. *PLoS One* 7:e43882. <http://dx.doi.org/10.1371/journal.pone.0043882>.
32. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, Damond F, Brun-Vezinet F, Mentre F, Descamps D, Yeni P. 2012. Virological outcome of patients displaying persistent low-level viremia comprised between 20 and 50 copies/mL. Abstr. 349. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA.
 33. Montaner J, British Columbia Centre for Excellence in HIV/AIDS Therapeutic Guidelines Committee. 2011. Therapeutic guidelines: anti-retroviral treatment (ARV) of adult HIV infection. BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. http://www.cfenet.ubc.ca/sites/default/files/uploads/BCCfE%20Adult%20Therapeutic%20Guidelines_Jan2011.pdf.
 34. Verhofstede C, Van Wanseele F, Reynaerts J, Mangelschots M, Plum J, Fransen K. 2010. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. *J. Clin. Virol.* 47:335–339. <http://dx.doi.org/10.1016/j.jcv.2010.01.008>.
 35. Wiriden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M, Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V. 2009. Impact of discrepancies between the Abbott RealTime and Cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. *J. Clin. Microbiol.* 47:1543–1545. <http://dx.doi.org/10.1128/JCM.02134-08>.
 36. Wiriden M, Tubiana R, Fourati S, Thevenin M, Simon A, Canestri A, Ait-Arkoub Z, Soulie C, Marcelin AG, Katlama C, Calvez V. 2011. Upgraded Cobas AmpliPrep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations. *J. Clin. Microbiol.* 49:2700–2702. <http://dx.doi.org/10.1128/JCM.00061-11>.
 37. Adachi D, Benedet M, Tang JWT, Cloherty G. 2013. Comparative evaluation of plasma preparation tube (PPT) and EDTA samples using Roche's Cobas TaqMan HIV-1 and Abbott's RealTime HIV-1 v. 4.00 assays, poster TUPE262. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur, Malaysia, 30 June to 3 July 2013.
 38. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao JDC. 2009. Comparison of the Abbott RealTime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. *J. Clin. Microbiol.* 47: 889–895. <http://dx.doi.org/10.1128/JCM.02231-08>.
 39. Garrett NJ, Apea V, Nori A, Ushiro-Lumb I, Oliver AR, Bailly G, Clark DA. 2012. Comparison of the rate and size of HIV-1 viral load blips with Roche Cobas TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. *J. Clin. Virol.* 53:354–355. <http://dx.doi.org/10.1016/j.jcv.2011.12.024>.
 40. Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. 2013. Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2.0 assay: consequence at the cohort level. *PLoS One* 8:e74024. <http://dx.doi.org/10.1371/journal.pone.0074024>.
 41. Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, Burkhardt JH, Schumacher JE, Johnson VA. 2010. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 1.0 viral load test. *J. Acquir. Immune Defic. Syndr.* 54:442–444. <http://dx.doi.org/10.1097/QAL.0b013e3181d01d1d>.
 42. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. 2011. Performance evaluation of the Cobas/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. *J. Virol. Methods* 173:399–402. <http://dx.doi.org/10.1016/j.jviromet.2011.03.014>.
 43. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. 2011. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. *J. Virol. Methods* 175:261–265. <http://dx.doi.org/10.1016/j.jviromet.2011.04.015>.
 44. Hildorfer BB, Cillo AR, Besson GJ, Bedison MA, Mellors JW. 2012. New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. *Curr. HIV/AIDS Rep.* 9:91–100. <http://dx.doi.org/10.1007/s11904-011-0104-6>.
 45. Palmer S, Wiegand AP, Maldarelli F, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* 41:4531–4536.
 46. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbò A, Angeletti C, Capobianchi MR. 2011. Standardization and performance evaluation of “modified” and “ultrasensitive” versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. *J. Clin. Virol.* 52:17–22. <http://dx.doi.org/10.1016/j.jcv.2011.04.012>.
 47. Grgic I, Zidovec Lepej S, Vince A, Begovac J. 2010. Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison with Cobas Amplicor assay. *J. Clin. Virol.* 48:75–76. <http://dx.doi.org/10.1016/j.jcv.2010.02.009>.
 48. Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT. 2008. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. *Clin. Infect. Dis.* 47:1354–1357. <http://dx.doi.org/10.1086/592693>.